NexImmune Inc (NEXI)
3.06
+0.05
(+1.66%)
USD |
NASDAQ |
May 31, 16:00
3.02
-0.04
(-1.31%)
After-Hours: 20:00
NexImmune Total Liabilities (Quarterly): 6.024M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 6.024M |
December 31, 2023 | 5.084M |
September 30, 2023 | 6.308M |
June 30, 2023 | 6.472M |
March 31, 2023 | 7.086M |
December 31, 2022 | 10.76M |
September 30, 2022 | 9.959M |
June 30, 2022 | 9.813M |
Date | Value |
---|---|
March 31, 2022 | 7.921M |
December 31, 2021 | 7.271M |
September 30, 2021 | 7.432M |
June 30, 2021 | 5.483M |
March 31, 2021 | 6.105M |
December 31, 2020 | 27.06M |
September 30, 2020 | 15.93M |
December 31, 2019 | 3.107M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.107M
Minimum
Dec 2019
27.06M
Maximum
Dec 2020
8.863M
Average
7.179M
Median
Total Liabilities (Quarterly) Benchmarks
Mind Medicine Inc | 79.47M |
Candel Therapeutics Inc | 25.24M |
Ventyx Biosciences Inc | 25.08M |
NKGen Biotech Inc | 71.37M |
CERo Therapeutics Holdings Inc | -- |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 8.991M |
Shareholders Equity (Quarterly) | 2.967M |